MedVector Launches its Prime-Control Technology to Expand Subject Enrollment Beyond Clinical Trial Sites
March 25, 2021 – MedVector has begun the rollout of its Prime-Controltm Technology, to give contract research organizations (CROs) and pharma sponsors access to patients without triggering new clinical trial sites. MedVector is the only company that partners with CROs, sponsors, and patient recruitment companies to expand subject participation beyond existing clinical trial sites. Clinical…